MAYER, Jiří, Ivo PALÁSEK, Zdeněk POSPÍŠIL, Soňa ŠTRUNCOVÁ, Dana DVOŘÁKOVÁ, Marek BORSKÝ, Martin KLABUSAY, Michael DOUBEK, Yvona BRYCHTOVÁ and Zdeněk RÁČIL. Detection of molecular relapse of AML by very frequent quantitative monitoring of different molecular markers (Fusion transcripts and WTI) in different compartments (peripheral blood, bone marrow, and selected CD34+bone marrow cells) and its treatment... 2006.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Detection of molecular relapse of AML by very frequent quantitative monitoring of different molecular markers (Fusion transcripts and WTI) in different compartments (peripheral blood, bone marrow, and selected CD34+bone marrow cells) and its treatment...
Name in Czech Detekce molekulárního relapsu AML pomocí opakovaného monitoringu různých molekulárních markerů (fúzní transkripty a WT1) v různých složkách (periferní krev, kostní dřeň a CD34+ buňky kostní dřeně) a jeho léčení chemoterapií nebo gemtuzumab ozogamicinem
Authors MAYER, Jiří (203 Czech Republic, guarantor), Ivo PALÁSEK (203 Czech Republic), Zdeněk POSPÍŠIL (203 Czech Republic), Soňa ŠTRUNCOVÁ (203 Czech Republic), Dana DVOŘÁKOVÁ (203 Czech Republic), Marek BORSKÝ (203 Czech Republic), Martin KLABUSAY (203 Czech Republic), Michael DOUBEK (203 Czech Republic), Yvona BRYCHTOVÁ (203 Czech Republic) and Zdeněk RÁČIL (203 Czech Republic).
Edition 2006.
Other information
Original language English
Type of outcome Conference abstract
Field of Study 30200 3.2 Clinical medicine
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14110/06:00025785
Organization unit Faculty of Medicine
UT WoS 000242440401165
Keywords in English AML; molecular relapse; peripheral blood; bone marrow
Tags AML, bone marrow, molecular relapse, peripheral blood
Tags Reviewed
Changed by Changed by: Ing. Dana Dvořáková, CSc., učo 35969. Changed: 2/4/2010 09:43.
Abstract
The paper deals with Detection of molecular relapse of AML by very frequent quantitative monitoring of different molecular markers (Fusion transcripts and WTI) in different compartments (peripheral blood, bone marrow, and selected CD34+bone marrow cells) and its treatment.
Abstract (in Czech)
Článek o Detekce molekulárního relapsu AML pomocí opakovaného monitoringu různých molekulárních markerů (fúzní transkripty a WT1) v různých složkách (periferní krev, kostní dřeň a CD34+ buňky kostní dřeně) a jeho léčení chemoterapií nebo gemtuzumab ozogamicinem
Links
LC06024, research and development projectName: Centrum Jaroslava Hájka pro teoretickou a aplikovanou statistiku
Investor: Ministry of Education, Youth and Sports of the CR, Jaroslav Hájek Center for Theoretical and Applied Statistics
PrintDisplayed: 8/5/2024 23:49